Incyte
INCY
$57.05
Share price
0.00%
Change (1 day)
-13.82%
Change (1 year)
Categories
Incyte (INCY) - Total liabilities
Total liabilities on the balance sheet as of March 2024 : $1.74 B
According to Incyte's latest financial reports the company's total liabilities are $1.74 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Incyte - Total liabilities on balance sheet (from 2001 to 2024)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $1.59 B | 8.25% |
| 2022-12-31 | $1.47 B | 26.43% |
| 2021-12-31 | $1.16 B | 22.5% |
| 2020-12-31 | $0.94 B | 14.64% |
| 2019-12-31 | $0.82 B | 15.08% |
| 2018-12-31 | $0.71 B | 7.12% |
| 2017-12-31 | $0.67 B | -44.88% |
| 2016-12-31 | $1.21 B | 45.78% |
| 2015-12-31 | $0.83 B | -4.76% |
| 2014-12-31 | $0.87 B | 6.74% |
| 2013-12-31 | $0.82 B | 62.78% |
| 2012-12-31 | $0.50 B | -9.11% |
| 2011-12-31 | $0.55 B | -3.84% |
| 2010-12-31 | $0.57 B | -29.03% |
| 2009-12-31 | $0.81 B | 79.81% |
| 2008-12-31 | $0.45 B | 4.12% |
| 2007-12-31 | $0.43 B | -0.75% |
| 2006-12-31 | $0.43 B | 11.44% |
| 2005-12-31 | $0.39 B | -10.24% |
| 2004-12-31 | $0.43 B | 94.66% |
| 2003-12-31 | $0.22 B | -9.82% |
| 2002-12-31 | $0.24 B | -5.89% |
| 2001-12-31 | $0.26 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $54.57 B | 3,034.27% | 🇨🇭 Switzerland |
 Pfizer PFE | $137.21 B | 7,779.78% | 🇺🇸 USA |
 Eli Lilly LLY | $51.04 B | 2,831.44% | 🇺🇸 USA |
 Amgen AMGN | $90.92 B | 5,121.41% | 🇺🇸 USA |
 Ligand Pharmaceuticals LGND | $86.3 M | -95.04% | 🇺🇸 USA |
 Geron GERN | $0.14 B | -91.61% | 🇺🇸 USA |
 CTI BioPharma
CTIC | $0.13 B | -92.10% | 🇺🇸 USA |
 AVEO Oncology
AVEO | $72.38 M | -95.84% | 🇺🇸 USA |
 Ardelyx ARDX | $0.13 B | -92.49% | 🇺🇸 USA |